GS-8588
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 03, 2024
GS-8588, a novel envelope-targeting bispecific T-cell engager for HIV cure
(AIDS 2024)
- "The preclinical activity, pharmacokinetics, and safety profile support clinical investigation of GS-8588 as a therapeutic candidate for the elimination of latent HIV-infected cells, and potentially as part of an HIV cure regimen."
Human Immunodeficiency Virus • Infectious Disease • CD4 • CD69 • HLA-DRB1 • IL10 • IL2 • IL4 • IL6 • TNFA
1 to 1
Of
1
Go to page
1